Market Overview

Transcatheter Pulmonary Valve (TPV) is an artificial heart valve made from the jugular vein valve of a cow that is sewn into a small metal frame. Transcatheter pulmonary valve are delivery by system which, is a thin, hollow, and long tube (catheter) that delivers the transcatheter pulmonary valve into the heart without open heart surgery while the heart is beating.

Transcatheter pulmonary valve first compressed onto a balloon at the tip of the delivery catheter to deliver into the body, then balloon is inflated in the pulmonary heart valve to open up the transcatheter pulmonary valve and catheter is removed from the body, than it immediately becomes the new pulmonary heart valve.

Transcatheter pulmonary valve used in patients born with heart defects, who is having failing conduit. Transcatheter pulmonary valve helps patients to delay the time when a patient needs additional open heart surgery. Transcatheter pulmonary valve also reduces the total number of open heart surgeries a patient needs in life time.

Transcatheter Pulmonary Valve (TPV) market is driven by increasing prevalence of comorbidities like diabetes and cardiovascular diseases coupled with increasing incidence of Congestive Heart Diseases (CHD) among varied patient age groups. Transcatheter pulmonary valve mainly indicated for extension of functional life of RV-PA conduit, for restoring pulmonary valve competence, and for relieving conduit stenosis without inducing regurgitation in patients which makes the transcatheter pulmonary valve market lucrative over the forecast period.

In addition, valves effectives in prolonging the open heart surgeries backed with robust clinical effectiveness in three clinical trials is expected to boost the revenue growth of transcatheter pulmonary valve market over the forecast period. However, low target population for therapy and snail pace adoption in both developing and developed economies expected to may impact the transcatheter pulmonary valve market revenue growth negatively over the forecast period.

Transcatheter Pulmonary Valve (TPV) market has been segmented on the basis of product type, end user and region.

Based on the product type	Valves Delivery System
Based on end user	Hospitals More Than 500 bedded Hospitals 500-300 Bedded Hospitals Less Than 299 Bedded Hospitals Cardiology Centers

Transcatheter Pulmonary Valve (TPV) market is undergoing market changes due to promising clinical development of newer technologies in the pipeline and increasing demand for minimally invasice therapies among healthcare fraternity and patient groups. The first Transcatheter Pulmonary Valve (TPV) was introduced by Medtronic plc in 2010 under a Humanitarian Device Exemption (HDE), a regulatory approval for treatments intended for fewer than 4,000 U.S. patients per year. Later in 2015, Medtronic plc received Pre-Market Approval (PMA) from U.S. regulator Food and Drug Administration (FDA) company’s device Melody based on significant clinical evidence from three clinical trials.

Geographically, Transcatheter Pulmonary Valve (TPV) market is segmented into regions viz. North America, Latin America, Europe, Asia Pacific and Japan, Middle East and Africa. North America and Europe region is projected to maintain its lions share over the forecast period.

Advanced healthcare infrastructure, availability well equipped healthcare professionals is expected to propel the demand for Transcatheter Pulmonary Valve (TPV) during the forecast period in the above mentioned region. Asia Pacific region is expected to be the moderately growing regional market. Growing healthcare facilities, increased healthcare awareness, and conducive regulatory environment are mainly generating the demand for Transcatheter Pulmonary Valve (TPV) in the region.

The players in Transcatheter Pulmonary Valve (TPV) market include Medtronic plc., Edwards Lifesciences Corporation, VENUS MEDTECH etc.